Literature DB >> 25863260

Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: a mechanism possibly involved in hereditary multiple exostoses.

Julianne Huegel1, Motomi Enomoto-Iwamoto1, Federica Sgariglia1, Eiki Koyama1, Maurizio Pacifici2.   

Abstract

Hereditary multiple exostoses is a pediatric skeletal disorder characterized by benign cartilaginous tumors called exostoses that form next to growing skeletal elements. Hereditary multiple exostoses patients carry heterozygous mutations in the heparan sulfate (HS)-synthesizing enzymes EXT1 or EXT2, but studies suggest that EXT haploinsufficiency and ensuing partial HS deficiency are insufficient for exostosis formation. Searching for additional pathways, we analyzed presence and distribution of heparanase in human exostoses. Heparanase was readily detectable in most chondrocytes, particularly in cell clusters. In control growth plates from unaffected persons, however, heparanase was detectable only in hypertrophic zone. Treatment of mouse embryo limb mesenchymal micromass cultures with exogenous heparanase greatly stimulated chondrogenesis and bone morphogenetic protein signaling as revealed by Smad1/5/8 phosphorylation. It also stimulated cell migration and proliferation. Interfering with HS function both with the chemical antagonist Surfen or treatment with bacterial heparitinase up-regulated endogenous heparanase gene expression, suggesting a counterintuitive feedback mechanism that would result in further HS reduction and increased signaling. Thus, we tested a potent heparanase inhibitor (SST0001), which strongly inhibited chondrogenesis. Our data clearly indicate that heparanase is able to stimulate chondrogenesis, bone morphogenetic protein signaling, cell migration, and cell proliferation in chondrogenic cells. These properties may allow heparanase to play a role in exostosis genesis and pathogenesis, thus making it a conceivable therapeutic target in hereditary multiple exostoses.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25863260      PMCID: PMC4450318          DOI: 10.1016/j.ajpath.2015.02.014

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

Review 1.  Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes.

Authors:  W Wuyts; W Van Hul
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

2.  Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Authors:  G Cassinelli; C Lanzi; M Tortoreto; D Cominetti; G Petrangolini; E Favini; N Zaffaroni; C Pisano; S Penco; I Vlodavsky; F Zunino
Journal:  Biochem Pharmacol       Date:  2013-03-01       Impact factor: 5.858

3.  Involvement of Ext1 and heparanase in migration of mouse FBJ osteosarcoma cells.

Authors:  Yinan Wang; XiaoYan Yang; Sadako Yamagata; Tatsuya Yamagata; Toshinori Sato
Journal:  Mol Cell Biochem       Date:  2012-10-10       Impact factor: 3.396

Review 4.  Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses.

Authors:  Julianne Huegel; Federica Sgariglia; Motomi Enomoto-Iwamoto; Eiki Koyama; John P Dormans; Maurizio Pacifici
Journal:  Dev Dyn       Date:  2013-07-29       Impact factor: 3.780

5.  Pain, physical and social functioning, and quality of life in individuals with multiple hereditary exostoses in The Netherlands: a national cohort study.

Authors:  A L Goud; J de Lange; V A B Scholtes; S K Bulstra; S J Ham
Journal:  J Bone Joint Surg Am       Date:  2012-06-06       Impact factor: 5.284

6.  Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple Exostoses.

Authors:  Julianne Huegel; Christina Mundy; Federica Sgariglia; Patrik Nygren; Paul C Billings; Yu Yamaguchi; Eiki Koyama; Maurizio Pacifici
Journal:  Dev Biol       Date:  2013-03-01       Impact factor: 3.582

7.  A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.

Authors:  Kevin B Jones; Virginia Piombo; Charles Searby; Gail Kurriger; Baoli Yang; Florian Grabellus; Peter J Roughley; Jose A Morcuende; Joseph A Buckwalter; Mario R Capecchi; Andrea Vortkamp; Val C Sheffield
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  Intronic deletion and duplication proximal of the EXT1 gene: a novel causative mechanism for multiple osteochondromas.

Authors:  Cathelijn J F Waaijer; Marcel G T Winter; Christianne M A Reijnders; Daniëlle de Jong; S John Ham; Judith V M G Bovée; Károly Szuhai
Journal:  Genes Chromosomes Cancer       Date:  2013-01-23       Impact factor: 5.006

Review 9.  Heparanase: busy at the cell surface.

Authors:  Liat Fux; Neta Ilan; Ralph D Sanderson; Israel Vlodavsky
Journal:  Trends Biochem Sci       Date:  2009-09-03       Impact factor: 13.807

10.  Heparanase induces endothelial cell migration via protein kinase B/Akt activation.

Authors:  Svetlana Gingis-Velitski; Anna Zetser; Moshe Y Flugelman; Israel Vlodavsky; Neta Ilan
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

View more
  20 in total

1.  Heparan sulfate antagonism alters bone morphogenetic protein signaling and receptor dynamics, suggesting a mechanism in hereditary multiple exostoses.

Authors:  Christina Mundy; Evan Yang; Hajime Takano; Paul C Billings; Maurizio Pacifici
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

Review 2.  Hereditary Multiple Exostoses: a review of clinical appearance and metabolic pattern.

Authors:  Giovanni Beltrami; Gabriele Ristori; Guido Scoccianti; Angela Tamburini; Rodolfo Capanna
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

3.  NFAT restricts osteochondroma formation from entheseal progenitors.

Authors:  Xianpeng Ge; Kelly Tsang; Lizhi He; Roberto A Garcia; Joerg Ermann; Fumitaka Mizoguchi; Minjie Zhang; Bin Zhou; Bin Zhou; Antonios O Aliprantis
Journal:  JCI Insight       Date:  2016-04

Review 4.  Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments.

Authors:  Maurizio Pacifici
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

5.  Extracellular Matrix Mediates BMP-2 in a Model of Temporomandibular Joint Osteoarthritis.

Authors:  Maya Shirakura; Vardit Kram; Jennifer Robinson; Sheena Sikka; Tina M Kilts; Sunil Wadhwa; Marian F Young
Journal:  Cells Tissues Organs       Date:  2017-04-19       Impact factor: 2.481

6.  Osteochondroma formation is independent of heparanase expression as revealed in a mouse model of hereditary multiple exostoses.

Authors:  Christina Mundy; Juliet Chung; Eiki Koyama; Stuart Bunting; Rajeev Mahimkar; Maurizio Pacifici
Journal:  J Orthop Res       Date:  2022-01-22       Impact factor: 3.102

7.  Domains with highest heparan sulfate-binding affinity reside at opposite ends in BMP2/4 versus BMP5/6/7: Implications for function.

Authors:  Paul C Billings; Evan Yang; Christina Mundy; Maurizio Pacifici
Journal:  J Biol Chem       Date:  2018-08-06       Impact factor: 5.157

8.  Excess BMP Signaling in Heterotopic Cartilage Forming in Prg4-null TMJ Discs.

Authors:  T E Bechtold; C Saunders; C Mundy; H Um; R S Decker; I Salhab; N Kurio; P C Billings; M Pacifici; H D Nah; E Koyama
Journal:  J Dent Res       Date:  2015-11-03       Impact factor: 6.116

9.  Hereditary multiple exostoses: are there new plausible treatment strategies?

Authors:  Maurizio Pacifici
Journal:  Expert Opin Orphan Drugs       Date:  2018-06-07       Impact factor: 0.694

10.  Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.

Authors:  Daniele Pala; Silvia Rivara; Marco Mor; Ferdinando Maria Milazzo; Giuseppe Roscilli; Emiliano Pavoni; Giuseppe Giannini
Journal:  Glycobiology       Date:  2016-01-13       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.